New Anticonvulsants: Interchangeability Issues and the Use of Generic Anticonvulsants in Clinical Practice

This article looks into interchangeability and therapeutic equivalence of innovator and generic anticonvulsants — the first-generation and new antiepileptic drugs (AEDs). The results of a number of clinical trials assessing therapeutic equivalence of generic AEDs support the opinion that these medicines could only be substituted provided an ultra-cautious approach is used, even if the case involves only one International Nonproprietary Name, including, but not limited to different dosage forms of one and the same product. The aim of the study was to analyse factors leading to incorrect assessment of therapeutic equivalence of new and generic anticonvulsant drugs, and to improve methodological approaches to conducting clinical trials of these products. The paper cites data from Russian and foreign sources which state that the substitution of AEDs in some patients in full remission may result in adverse reactions or relapse of seizures. The analysis of the experience of scientific, expert, and regulatory institutions made it possible to develop a course of actions to be used when substituting AEDs and conducting clinical trials that assess therapeutic equivalence of new and generic anticonvulsants. The proposed methodology will help minimise potential health risks brought about by various factors that result in incorrect assessment of AEDs therapeutic equivalence and interchangeability.

1. Belyaev OV, Konovalova TI, Volkova EA. Drug therapy of epilepsy in the Volgograd Region. Volgo-gradskiy nauchno-meditsinskiy zhurnal = Volgograd Journal of Medical Research. 2013;(1):37—8 (In Russ.)

2. Vlasov PN, Naumova GI, Drozhzhina GR. New antiepileptic drugs. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2008;(3):12-28 (In Russ.)

3. Gromov SA, Tabulina SD. The use of valproates-generics (Encorate chrono) in the treatment of epileptic patients. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2005;105(4):22-6 (In Russ.)

4. Editorial A. Resolution of meeting of Working Group of Russian League against epilepsy. Epilepsiya i parok-sizmalnye sostoyaniya = Epilepsia and Paroxyzmal Conditions. 2016;8(4):109-11 (In Russ.)

5. Romodanovsky DP, Goryachev DV, Solovieva AP, Eremenko NN. Principles of statistical evaluation of bioequivalence studies in the context of current regulatory requirements and legal acts. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya = The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2018;8(2):92-8 (In Russ.) https://doi.org/10.30895/1991-2919-2018-8-2-92-98

6. Bukatina TM, Pasternak EYu, Romanov BK, Alyautdin RN, Lepakhin VK, Kazakov AS, et al. Foreign Regulatory Recommendations. Bezopasnost’ i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2016;(1):38-40 (In Russ.) https://doi.org/10.30895/2312-7821-2016-0-1-38-40

7. Sokolov AV, Belousov YuB, Zyryanov SK, Nechaeva EB, Milkina SE. Ways to ensure the quality and safety of generic drugs. Farmakokinetika i farmakodinamika = Pharmacokinetics and Pharmacodynamics. 2012;1(4):43-9 (In Russ.)

8. Sankar R, Glauser TA. Understanding therapeutic equivalence in epilepsy. CNS Spectr. 2010;15(2):112-23. PMID: 20414156

9. LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008;70(22 Pt 2):2179-86. https://doi.org/10.1212/01.wnl.0000313154.55518.25

10. Shin JW, Chu K, Jung KH, Lee ST, Moon J, Lee SK. Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations. Int J Clin Pharmacol Ther. 2014;52(12):1017-22. https://doi.org/10.5414/CP202153

11. Pasternak EYu. Optimization of methods for assessing the interchangeability of drugs based on pharmacoepidemiological study of adverse reactions in the context of drug therapy. Cand. Med. Sci. [dissertation]. Moscow; 2017 (In Russ.)

12. Chen ML, Shah VP, Crommelin DJ, Shargel L, Bashaw D, Bhatti M, et al. Harmonization of regulatory approaches for evaluating therapeutic equivalence and interchangeability of multisource drug products: workshop summary report. AAPS J. 2011;13(4):556-64. https://doi.org/10.1208/s12248-011-9294-5

13. Hottinger M, Liang BA. Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs. Amer J Law Med. 2012;38(4):667-89. PMID: 23356099

14. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs. 2006;15(6):637-47. https://doi.org/10.1517/13543784.15.6.637

15. Saldana-Cruz AM, Sanchez-Corona J, Marquez de Santiago DA, Garcia-Zapien AG, Flores-Martinez SE. Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450. Rev Neurol. 2013;56(9):471-9. PMID: 23629749

16. Steinhoff BJ, Runge U, Witte OW, Stefan H, Hufnagel A, Mayer T, Kramer G. Substitution of anticonvulsant drugs. Ther and Clin Risk Manag. 2009;5(3):449-57. PMID: 19707254

17. Atif M, Azeem M, Sarwar MR. Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. Springerplus. 2016;(5):182. https://doi.org/10.1186/s40064-016-1824-2

18. Depondt C. Epilepsy pharmacogenetics: science or fiction? Med Sci (Paris). 2013;29(2):189-93. https://doi.org/10.1051/medsci/2013292017

19. Glauser TA. Biomarkers for antiepileptic drug response. Biomark Med. 2011;5(5):635-41. https://doi.org/10.2217/bmm.11.75

20. Kovalenko VN, Viktorov AP, eds. Compendium 2011 — Medicines. Kiev: MORION; 2011 (In Russ.)

21. Ochoa JG, Riche W. Antiepileptic drugs. Available from: https://emedicine.medscape.com/article/1187334-overview

22. Yuriev KL. Pharmacotherapy for epilepsy in adults: review of the evidence-based clinical practice guidelines. Ukrainskiy meditsinskiy zhurnal = Ukrainian medical journal. 2004;(4):5-27 (In Russ.)

23. Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009;61(2):197-216. PMID: 19443931

24. Hansen RN, Nguyen HP, Sullivan SD. Bioequivalent antiepileptic drug switching and the risk of seizure-related events. Epilepsy Res. 2013;106(1-2):237-43. https://doi.org/10.1016/j.eplepsyres.2013.04.010

25. Yu LX, Li B, eds. FDA Bioequivalence Standards. New York: Springer; 2014.

26. Yu LX, Jiang W, Zhang X, Lionberger R, Makhlouf F, Schuir-mann DJ, et al. Novel bioequivalence approach for narrow therapeutic index drugs. Clin Pharmacol Ther. 2015;97(3):286-91. https://doi.org/10.1002/cpt.28